|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
|
|---|---|---|---|---|
| Assets: | ||||
| Cash and cash equivalents | ||||
| Deferred offering expenses | ||||
| Expense support receivable | ||||
| Total assets | ||||
| Liabilities: | ||||
| Organizational and offering expenses payable | ||||
| Professional fees payable | ||||
| Board of Trustees fees payable | ||||
| Due to Adviser | ||||
| Total liabilities | ||||
| Net Assets: | ||||
| Common shares of beneficial interest, $0.001 par value, unlimited shares authorized, 40 shares issued and outstanding at June 30, 2026 and December 31, 2025 | ||||
| Additional paid-in capital | ||||
| Total net assets | ||||
| Total liabilities and net assets | ||||
| Net asset value per common share of beneficial interest |
Loading...
